Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone720-696-8100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.29 million
Profitability
Miscellaneous
Employees103
OptionableOptionable
Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions
What is Viveve Medical's stock symbol?
Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."
How were Viveve Medical's earnings last quarter?
Viveve Medical Inc (NASDAQ:VIVE) issued its quarterly earnings results on Thursday, August, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.01. The firm had revenue of $5.53 million for the quarter, compared to analyst estimates of $4.97 million. Viveve Medical had a negative return on equity of 838.28% and a negative net margin of 243.98%. View Viveve Medical's Earnings History.
When is Viveve Medical's next earnings date?
What guidance has Viveve Medical issued on next quarter's earnings?
Viveve Medical updated its FY 2019 earnings guidance on Wednesday, January, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $22.2 million.Viveve Medical also updated its FY 2018 guidance to EPS.
What price target have analysts set for VIVE?
5 brokerages have issued 1-year price targets for Viveve Medical's stock. Their predictions range from $1.00 to $10.00. On average, they expect Viveve Medical's stock price to reach $5.20 in the next year. This suggests a possible upside of 381.5% from the stock's current price. View Analyst Price Targets for Viveve Medical.
What is the consensus analysts' recommendation for Viveve Medical?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viveve Medical.
What are Wall Street analysts saying about Viveve Medical stock?
Here are some recent quotes from research analysts about Viveve Medical stock:
- 1. Maxim Group analysts commented, "Market open, VIVE reported preliminary 4Q18 revenue that was slightly above both our estimate and consensus. However, the company also introduced full-year 2019 revenue guidance that was slightly below both our estimate and consensus. VIVE announced a strategic restructuring that is expected to reduce its workforce by 36% in order to decrease operating costs. Based on its recent capital raise and strategic realignment plan, we believe VIVE has sufficient cash to fund operations through 1Q20. The company plans to report full 4Q18 results in March 2019." (1/17/2019)
- 2. Mizuho analysts commented, "We expect the trends in utilization and pricing to continue in 2018. FDA Approval of IDE to Conduct VIVEVE2 Clinical Trial. The FDA approved Viveve’s IDE to conduct a sexual function study in the U.S. The study is expected to start in 2Q18 and will include approximately 250 patients across 25 clinical sites in the U.S. and Canada. The primary endpoint will measure the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Data from the study is expected in 2H19. Cash Position and Upcoming Catalysts. Viveve’s current cash position stands at approximately $55.7 mil following a recent $35.0 mil equity offering in February." (3/20/2018)
Has Viveve Medical been receiving favorable news coverage?
Headlines about VIVE stock have trended positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Viveve Medical earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Viveve Medical's key competitors?
Some companies that are related to Viveve Medical include Stereotaxis (STXS), BioSig Technologies (BSGM), Edap Tms (EDAP), IRIDEX (IRIX), Second Sight Medical Products (EYES), Soleno Therapeutics (SLNO), Precision Optics (PEYE), Digirad (DRAD), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU), Aradigm (ARDM), Vaso (VASO), CHF Solutions (CHFS), Nexeon Medsystems (NXNN) and Reshape Lifesciences (RSLS).
Who are Viveve Medical's key executives?
Viveve Medical's management team includes the folowing people:
- Mr. Scott C. Durbin, CEO & Director (Age 50)
- Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 61)
- Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 61)
- Mr. Jim B. Robbins, VP of Fin. & Admin., Principal Accounting Officer & Principal Financial Officer (Age 55)
- Mr. Martin Kerber, VP of Operations
When did Viveve Medical IPO?
(VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.
Who are Viveve Medical's major shareholders?
Viveve Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (20.87%), RTW Investments LP (14.21%), Stonepine Capital Management LLC (10.84%), Polar Capital LLP (2.26%), Geode Capital Management LLC (0.69%) and Bank of New York Mellon Corp (0.14%). Company insiders that own Viveve Medical stock include James G Atkinson, Patricia Scheller and Scott Durbin. View Institutional Ownership Trends for Viveve Medical.
Which major investors are selling Viveve Medical stock?
Which major investors are buying Viveve Medical stock?
VIVE stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, RTW Investments LP, Bank of New York Mellon Corp, Sargent Investment Group LLC and Geode Capital Management LLC. Company insiders that have bought Viveve Medical stock in the last two years include James G Atkinson, Patricia Scheller and Scott Durbin. View Insider Buying and Selling for Viveve Medical.
How do I buy shares of Viveve Medical?
Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viveve Medical's stock price today?
One share of VIVE stock can currently be purchased for approximately $1.08.
How big of a company is Viveve Medical?
Viveve Medical has a market capitalization of $34.06 million and generates $15.29 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Viveve Medical employs 103 workers across the globe.
What is Viveve Medical's official website?
How can I contact Viveve Medical?
Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]
MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
